Abstract
New fast methods for the determination of pharmacokinetic behaviour of potential drug candidates are receiving increasing interest. We present a new homogeneous method for the determination of drug binding and drug competition for human serum albumin and α1-acid glycoprotein that is amenable to high-throughput-screening. It is based on selective fluorescent probes and the measurement of fluorescence polarization. This leads to decreased interference with fluorescent drugs as compared with previously published methods based on similar probes and the measurement of fluorescence intensity. The binding of highly fluorescent drugs that still interfere with the probes can be measured by simply titrating the drugs in a two-component system with the serum protein. The assay may also be used to discover strongly binding protein ligands that are interesting for drug-targeting strategies. Additionally, binding data could be obtained from larger libraries of compounds for in silico predictive pharmacokinetics.
Similar content being viewed by others
References
Eddershaw PJ, Beresford AP, Bayliss MK (2000) Drug Discov Today 5:409–414
van de Waterbeemd H (2002) Curr Opin Drug Discov Dev 5:33–43
Fasano M, Curry S, Terreno E, Galliano M, Fanali G, Narciso P, Notari S, Ascenzi P (2005) IUBMB Life 57:787–796
Carter DC, Ho JX (1994) Adv Protein Chem 45:153–203
Solomon HM, Schrogie JJ, Williams D (1968) Biochem Pharmacol 17:143–151
Kaliszan R (1998) J Chromatogr B 715:229–244
Colmenarejo G, Alvarez-Pedraglio A, Lavandera JL (2001) J Med Chem 44:4370–4378
Epps DE, Raub TJ, Kezdy FJ (1995) Anal Biochem 227:342–350
Frostell-Karlsson A, Remaeus A, Roos H, Andersson K, Borg P, Hamalainen M, Karlsson R (2000) J Med Chem 43:1986–1992
Rich RL, Day YS, Morton TA, Myszka DG (2001) Anal Biochem 296:197–207
Epps DE, Raub TJ, Caiolfa V, Chiari A, Zamai M (1999) J Pharm Pharmacol 51:41–48
Parikh HH, McElwain K, Balasubramanian V, Leung W, Wong D, Morris ME, Ramanathan M (2000) Pharm Res 17:632–637
Jameson DM, Croney JC (2003) Comb Chem High Throughput Screen 6:167–173
Owicki JC (2000) J Biomol Screen 5:297–306
Sportsman JR, Daijo J, Gaudet EA (2003) Comb Chem High Throughput Screen 6:195–200
Burke TJ, Loniello KR, Beebe JA, Ervin KM (2003) Comb Chem High Throughput Screen 6:183–194
de Jong LA, Uges DR, Franke JP, Bischoff R (2005) J Chromatogr B 829:1–25
Saldanha SA, Kaler G, Cottam HB, Abagyan R, Taylor SS (2006) Anal Chem 78:8265–8272
Hu Y, Helm JS, Chen L, Ginsberg C, Gross B, Kraybill B, Tiyanont K, Fang X, Wu T, Walker S (2004) Chem Biol 11:703–711
Antczak C, Shum D, Escobar S, Bassit B, Kim E, Seshan VE, Wu N, Yang G, Ouerfelli O, Li YM, Scheinberg DA, Djaballah H (2007) J Biomol Screen (in press)
Klumpp M, Boettcher A, Becker D, Meder G, Blank J, Leder L, Forstner M, Ottl J, Mayr LM (2006) J Biomol Screen 11:617–633
Moreno F, Gonzalez-Jimenez J (1999) Chem Biol Interact 121:237–252
Moreno F, Cortijo M, Gonzalez-Jimenez J (1999) Photochem Photobiol 69:8–15
Sudlow G, Birkett DJ, Wade DN (1976) Mol Pharmacol 12:1052–1061
Sudlow G, Birkett DJ, Wade DN (1975) Mol Pharmacol 11:824–832
Israili ZH, Dayton PG (2001) Drug Metab Rev 33:161–235
Maruyama T, Otagiri M, Takadate A (1990) Chem Pharm Bull 38:1688–1691
Cheng Y, Prusoff WH (1973) Biochem Pharmacol 22:3099–3108
Kenakin TP (1993) In: Pharmacologic analysis of drug/receptor interaction, 2nd edn. Raven, New York, pp 385–410
Swillens S (1995) Mol Pharmacol 47:1197–1203
Munson PJ, Rodbard D (1988) J Recept Res 8:533–546; Erratum 1989-1990, 1989, 1511
Kratochwil NA, Huber W, Muller F, Kansy M, Gerber PR (2002) Biochem Pharmacol 64:1355–1374
Kopitar Z, Weisenberger H (1971) Arzneim Forsch 21:859–862
Hartung G, Stehle G, Sinn H, Wunder A, Schrenk HH, Heeger S, Kranzle M, Edler L, Frei E, Fiebig HH, Heene DL, Maier-Borst W, Queisser W (1999) Clin Cancer Res 5:753–759
Kratz F, Muller-Driver R, Hofmann I, Drevs J, Unger C (2000) J Med Chem 43:1253–1256
Warnecke A, Kratz F (2003) Bioconjug Chem 14:377–387
Votano JR, Parham M, Hall LM, Hall LH, Kier LB, Oloff S, Tropsha A (2006) J Med Chem 49:7169–7181
Zhang JH, Chung TD, Oldenburg KR (1999) J Biomol Screen 4:67–73
Piafsky KM, Borga O (1977) Clin Pharmacol Ther 22:545–549
Brinkschulte M, Breyer-Pfaff U (1980) Naunyn Schmiedebergs Arch Pharmacol 314:61–66
Kornguth ML, Hutchins LG, Eichelmann BS (1981) Biochem Pharmacol 30:2345–2441
Israili ZH, El-Attar H (1983) Clin Pharmacol Ther 33:255
Israili ZH, Bharmal F, Tiliakos N (1985) Fed Proc 44:1124
Brunner F, Muller WE (1987) J Pharm Pharmacol 39:986–990
McGowan FX, Reiter MJ, Pritchett EL, Shand DG (1983) Clin Pharmacol Ther 33:485–490
Acknowledgements
We thank Roche Diagnostics (Penzberg, Germany) for financial support, L. Stecher and S. Wittich for exploratory experiments and W. Sippl (Halle) for the 3D graphic for the online edition.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Mathias, U., Jung, M. Determination of drug–serum protein interactions via fluorescence polarization measurements. Anal Bioanal Chem 388, 1147–1156 (2007). https://doi.org/10.1007/s00216-007-1351-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00216-007-1351-7